Acute effects of supplemental oxygen therapy (SOT) using different nasal cannulas on walking capacity in patients with idiopathic pulmonary fibrosis (IPF) – a randomized cross-over trial
| Autor: | Klaus Kenn, Inga Jarosch, Daniela Leitl, Daniela Reimann, Tessa Schneeberger, Rainer Gloeckl, Andreas Rembert Koczulla |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Acute effects
Respiratory rate business.industry Exercise intolerance medicine.disease_cause medicine.disease Crossover study Hypoxemia 03 medical and health sciences Idiopathic pulmonary fibrosis 0302 clinical medicine 030228 respiratory system Anesthesia medicine In patient 030212 general & internal medicine medicine.symptom business Nasal cannula |
| Zdroj: | Rehabilitation and chronic care. |
| DOI: | 10.1183/13993003.congress-2019.oa3573 |
| Popis: | Background: In patients with IPF exercise intolerance is often associated with hypoxemia. Therefore, SOT may be offered. The Oxymizer® is a nasal cannula incorporating an internal reservoir with the potential to deliver higher oxygen (O2) doses to the patient on the same O2-flow compared to a conventional nasal cannula (CNC). Objectives: Primary aim was to investigate the effects of SOT delivered via Oxymizer compared to a CNC in hypoxemic IPF-patients on walking capacity. Secondary aim was to evaluate the effects on O2-saturation (SpO2), heart- and breathing rate at isotime (end of shortest endurance shuttle walk test; ESWT). Methods: 26 patients with a confirmed diagnosis of IPF and SOT-indication during exercise were consecutively included in this trial. After an initial incremental shuttle walk test, patients performed, in randomized order and with a 24h-resting period between tests, two ESWTs - one with Oxymizer and one with CNC. Results: 22 patients (70±7years; VC:54±15%/pred) completed all tests. Walking capacity was significantly greater while using the Oxymizer compared to CNC (523±369vs.419±332sec, p=0.027). 15 patients (68%) walked longer with the Oxymizer. At isotime, SpO2 (81.6±8.8 vs.78.5±8.1%, p=0.001) was significantly higher while heart- (112±16vs.118±13bpm) and breathing rate (38±8vs.41±8bpm) were significantly (p Conclusion: SOT when provided by the Oxymizer showed significant and clinically relevant benefits on walking capacity in IPF-patients by improving physiological parameters. However, only 8 (36%) patients would prefer the Oxymizer for their daily use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|